SCHEMBL427550

SCHEMBL427550

CCCc1cc(OC)cc(OC)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 1/20 0.55
ALDH1A1 P00352 3/20 0.55
PTGS2 P35354 1/20 0.55
CALM1 P0DP23 3/20 0.52
AKR1B1 P15121 1/20 0.52
DAO P14920 1/20 0.46
TSHR P16473 2/20 0.44
GABRA1 P14867 1/20 0.44
GABRG2 P18507 1/20 0.44
GABRB3 P28472 1/20 0.44
GABRA3 P34903 1/20 0.44
GABRA2 P47869 1/20 0.44
GABRB2 P47870 1/20 0.44
MAPK1 P28482 1/20 0.44
CYP1A1 P04798 1/20 0.42
CYP1B1 Q16678 1/20 0.42
FGFR1 P11362 1/20 0.42
KDR P35968 1/20 0.42
CNR1 P21554 1/20 0.42
CNR2 P34972 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13980912 0.89 PTGS2 (0.50) CYP19A1ALDH1A1PTGS2CALM1AKR1B1
SCHEMBL9491787 0.87 CYP19A1 (0.68) CYP19A1ALDH1A1PTGS2CALM1AKR1B1
SCHEMBL13369436 0.87 PTGS2 (0.49) CYP19A1ALDH1A1PTGS2CALM1AKR1B1
SCHEMBL9279920 0.86 PTGS2 (0.67) CYP19A1ALDH1A1PTGS2CALM1AKR1B1
SCHEMBL16951830 0.85 DAO (0.53) CYP19A1ALDH1A1PTGS2CALM1AKR1B1
SCHEMBL16956526 0.85 PTGS2 (0.47) CYP19A1ALDH1A1PTGS2CALM1AKR1B1
SCHEMBL14288599 0.85 PTGS2 (0.47) CYP19A1ALDH1A1PTGS2CALM1AKR1B1
SCHEMBL13548286 0.85 PTGS2 (0.47) CYP19A1ALDH1A1PTGS2CALM1AKR1B1
SCHEMBL20098971 0.85 CYP19A1 (0.56) CYP19A1ALDH1A1PTGS2CALM1AKR1B1
SCHEMBL30195497 0.85 PTGS2 (0.77) CYP19A1PTGS2CALM1AKR1B1GABRA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 174 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4711359-A2 RESCORCINOLS, METHODS FOR THEIR MANUFACTURE, AND USES THEREOF Jazz Pharmaceuticals Research UK Limited (GB) 2026-03-18 EP disclosed
EP-4709724-A1 ANTICONVULSIVE COMPOUNDS AND USES THEREOF Jazz Pharmaceuticals Research UK Limited (GB) 2026-03-18 EP disclosed
WO-2025078811-A1 CANNABINOID COMPOUNDS AND USES THEREOF JAZZ PHARMACEUTICALS RESEARCH UK LIMITED (GB) 2025-04-17 WO disclosed
EP-3722276-B1 PROCESS FOR THE PRODUCTION OF PURIFIED CANNABIDIOL PURISYS LLC (US) 2025-01-08 EP disclosed
CN-113905730-B Solid compositions of cannabinoid co-crystals 南迪亚公司 2025-01-03 CN disclosed
WO-2024236275-A1 ANTICONVULSIVE COMPOUNDS AND USES THEREOF JAZZ PHARMACEUTICALS RESEARCH UK LIMITED (GB) 2024-11-21 WO disclosed
US-20240254066-A1 RESCORCINOLS, METHODS FOR THEIR MANUFACTURE, AND USES THEREOF JAZZ PHARMACEUTICALS RESEARCH UK LIMITED (GB) 2024-08-01 US disclosed
US-11993563-B2 Solid compositions of cocrystals of cannabinoids ENANTIA S.L. (ES) 2024-05-28 US disclosed
CN-117396455-A Resorcinol, its manufacturing method and use 吉伟研究有限公司 2024-01-12 CN disclosed
US-20230203096-A1 EPHA4 TARGETING COMPOUNDS AND METHODS OF USE THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-06-29 US disclosed
EP-1049662-A1 INHIBITORS OF ALPHA4 MEDIATED CELL ADHESION TANABE SEIYAKU CO., LTD. (JP) 2000-11-08 EP disclosed
WO-2000041505-A2 ANTHRANILIC ACID DERIVATIVES WARNER-LAMBERT COMPANY (US) 2000-07-20 WO disclosed
WO-2000042003-A1 BENZENESULFONAMIDE DERIVATIVES AND THEIR USE AS MEK INHIBITORS WARNER-LAMBERT COMPANY (US) 2000-07-20 WO disclosed
WO-2000042029-A1 1-HETEROCYCLE SUBSTITUTED DIARYLAMINES WARNER-LAMBERT COMPANY (US) 2000-07-20 WO disclosed
WO-2000041994-A1 4-ARYLAMINO, 4-ARYLOXY, AND 4-ARYLTHIO DIARYLAMINES AND DERIVATIVES THEREOF AS SELECTIVE MEK INHIBITORS WARNER-LAMBERT COMPANY (US) 2000-07-20 WO disclosed
WO-2000042022-A1 BENZOHETEROCYCLES AND THEIR USE AS MEK INHIBITORS WARNER-LAMBERT COMPANY (US) 2000-07-20 WO disclosed
WO-2000042002-A1 SULPHOHYDROXAMIC ACIDS AND SULPHOHYDROXAMATES AND THEIR USE AS MEK INHIBITORS WARNER-LAMBERT COMPANY (US) 2000-07-20 WO disclosed
WO-1999036393-A1 INHIBITORS OF α4 MEDIATED CELL ADHESION TANABE SEIYAKU CO., LTD. (JP) 1999-07-22 WO disclosed
WO-1998008837-A1 PHENYLBUTANOL DERIVATIVES, METHODS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THEREOF FARMACON, INC. (US) 1998-03-05 WO disclosed
US-5399785-A Applying methylenebis/2,4-dihydroxybenzene/ derivatives; cosmetics NIPPON PAINT CO., LTD. (JP) 1995-03-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230203096-A1 EPHA4 TARGETING COMPOUNDS AND METHODS OF USE THEREOF EPHA4, EPHA1, EPHA5 CYP19A1 1213/4885ALDH1A1 1458/4885PTGS2 4009/4885
US-11993563-B2 Solid compositions of cocrystals of cannabinoids CNR1, CNR2, FAAH CYP19A1 227/4885ALDH1A1 1780/4885PTGS2 2547/4885
US-20240254066-A1 RESCORCINOLS, METHODS FOR THEIR MANUFACTURE, AND USES THEREOF REN, CYP46A1, NQO1 CYP19A1 257/4885ALDH1A1 796/4885PTGS2 1616/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.